Humasis Co

Humasis Co EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Humasis Co (205470.KQ) as of Nov 9, 2026 is 68.17 %. In the previous year, Year-over-Year EBITDA Growth was 26.15 % — a change of 160.72% (higher).

EBITDA Growth YoY

68.17 %

YoY

160.72%

Last updated:

Year-over-Year EBITDA Growth of Humasis Co is 2025 68.17 % . Year-over-Year EBITDA Growth of Humasis Co was 2024 26.15 % . It decreases by 160.72% higher compared to the previous year.

The Humasis Co EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-1,294.47 KRW
Jan 1, 2019
18.10 KRW
Jan 1, 2020
3,339.88 KRW
Jan 1, 2021
669.09 KRW
Jan 1, 2022
6.51 KRW
Jan 1, 2023
-128.49 KRW
Jan 1, 2024
26.15 KRW
Jan 1, 2025
68.17 KRW
The Humasis Co EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
68.17 %+160.72%
26.15 %-120.35%
-128.49 %-2,073.44%
6.51 %-99.03%
669.09 %-79.97%
3,339.88 %+18,349.58%
18.10 %-101.40%
-1,294.47 %+2,588.55%
-48.15 %-526.57%
11.29 %-134.80%
-32.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Year-over-Year EBITDA Growth of Humasis Co is 68.17 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Humasis Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humasis Co

All Key Metrics — Humasis Co